<DOC>
	<DOCNO>NCT00996567</DOCNO>
	<brief_summary>Multicenter , open phase 2 study patient malignant mesothelioma . Standardly , 4 6 cycle palliative chemotherapy , platinum combination pemetrexed , give . Despite treatment , median survival poor ( 9-12 month ) . By combine conventional cytotoxic agent novel agent , hopefully treatment survival approve . Cetuximab Erbitux monoclonal antibody EGFR ( Epidermal Growth Factor Receptor ) . By block receptor , interfere cel growth division . Most mesothelioma show strong expression EGFR protein . Apart , Cetuximab also antibody-dependent cell-mediated cytotoxicity ( ADCC ) . In trial , patient treat standard chemotherapy , combine Cetuximab weekly . After maximum 6 cycle chemotherapy , administration Cetuximab continue disease progression . Every 6 week , CT scan do evaluate therapy . Most common side effect Cetuximab acneiform rash . The translation research program consist determination EGFR- K-Ras mutation tumor tissue correlation outcome . In first part trial , 18 patient include . After positive interim analysis , total 43 patient include .</brief_summary>
	<brief_title>A Study Cetuximab Combined With Cisplatin Carboplatin/Pemetrexed First Line Treatment Patients With Malignant Pleural Mesothelioma .</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically proven malignant pleural mesothelioma , epitheloid subtype Recurrent radical surgery disease consider suitable radical treatment EGFR IHC + assess DAKO kit least 1 % cell show stain Performance status WHO 0 1 Life expectancy &gt; 12 week Weight loss &lt; 10 % last 3 month Adequate bone marrow reserve , renal hepatic function Measurable disease ( modified RECIST ) No prior chemotherapy No prior malignancy , except long 5 yr ago adequately treat basocellular skin situ cervical cancer No uncontrolled infection Written inform consent . Male/Female &gt; 18 year Evidence brain leptomeningeal metastases Patients unable interrupt aspirin , nonsteroidal antiinflammatory drug 5day period start 2 day administration pemetrexed ( 8day period long act agent piroxicam ) Patients treat folic acid vitamin B 12 Patients treat dexamethasone . Presence clinically detectable ( physical examination ) thirdspace fluid collection , example ascites pleural effusion control drainage procedure prior study entry . Use investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Malignant mesothelioma</keyword>
</DOC>